ERBB2 and neoplasm: More recently, a fully human IgE also targeting human HER2/neu with the variable regions of the scFv C6MH3-B1 has been described and shown to have in vivo anti-cancer activity in human FcεRIα transgenic mice in a passive immunotherapeutic setting against a syngeneic tumor expressing human HER2/neu[25].